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Many sarcoidosis-associating immunological genes have been shown to be
shared between other immune-mediated diseases. In Finnish sarcoidosis patients,
good prognosis subjects more commonly have HLA-DRB1∗03:01 and/or
HLA-DRB1∗04:01-DPB1∗04:01 haplotype, but no marker for persistent disease
have been found. The objective was to further pinpoint genetic differences between
prognosis subgroups in relation to the HLA markers. Whole-exome sequencing was
conducted for 72 patients selected based on disease activity (resolved disease, n = 36;
persistent disease, n = 36). Both groups were further divided by the HLA markers
(one/both markers, n = 18; neither of the markers, n = 18). The Finnish exome data
from the Genome Aggregation Database was used as a control population in the WES
sample. Statistical analyses included single-variant analysis for common variants and
gene level analysis for rare variants. We attempted to replicate associated variants
in 181 Finnish sarcoidosis patients and 150 controls. An association was found in
chromosome 1p36.21 (AADACL3 and C1orf158), which has recently been associated
with sarcoidosis in another WES study. In our study, variations in these genes were
associated with resolved disease (AADACL3, p = 0.0001 and p = 0.0003; C1orf158,
p = 7.03E-05). Another interesting chromosomal region also peaked, Leucocyte
Receptor Complex in 19q13.42, but the association diminished in the replication
sample. In conclusion, this WES study supports the previously found association in the
region 1p36.21. Furthermore, a novel to sarcoidosis region was found, but additional
studies are warranted to verify this association.
Keywords: sarcoidosis, prognosis, MHC, whole exome sequencing, 1p36.21, leucocyte receptor complex
INTRODUCTION
Sarcoidosis is granulomatous disease characterized by the presence of non-caseating granulomas
in affected organs. Sarcoidosis can affect any organ in the body and the disease course can be self-
limited or chronic (1). These different outcomes have led to the classification of sarcoidosis based
on prognosis: resolved disease, i.e., duration of disease<2 years and persistent disease with a longer
duration (≥2 years) (2).
Exact etiology of sarcoidosis is still unclear. The heterogeneity of sarcoidosis in clinical course
and organ involvement has led to the hypothesis that sarcoidosis might not be one disease, but
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consists of several disease entities, each with distinct genetic
associations (3). This may explain why no single sarcoidosis-
associated variant has been found, but a wide range of genes
with relatively small effects. With a current knowledge it seems,
that the genetic susceptibility to sarcoidosis is mainly affected
by the genetic variation in the genes and pathways related to
granuloma formation and immune response. The MHC region
in chromosome 6p21.3 contains multiple genes essential for the
immune system. The association for sarcoidosis in theMHC have
been found in all classes through I to III (4, 5). In our previous
studies in Finnish patients, an association between class II HLA-
DRB1∗03:01 and the haplotype consisting of HLA-DRB1∗04:01-
DPB1∗04:01 and good prognosis compared to poor prognosis
was found (44.9 vs. 22.7%; p= 0.001; OR= 2.78; 95% CI= 1.45–
5.24) (6, 7).
Besides theMHC, other susceptible sarcoidosis risk/protective
chromosome regions and genes have been found throughout the
genome. Beside classical candidate-gene approaches, genome-
wide association analyses (GWAS) have become method of
choice nowadays. However, as sarcoidosis is a rare disease,
its prevalence in Finland being 28 per 100,000 (8), collections
of large case-control materials for GWAS are demanding. A
possible new method for finding causality in genetics behind
sarcoidosis is whole-exome sequencing (WES). The exome
sequences encompass only about 2% of the human genome
but harbors about 85% of all described disease-causing variants
(9), making smaller sample sizes sufficient for identification of
novel genes.
Aim of this study was to further characterize genetic
differences between Finnish sarcoidosis prognosis utilizing
whole-exome sequencing method in the subset of 72 patients
and to replicate the findings in a bigger data set of 188 Finnish
patients. In Finnish patients, subjects with good prognosis are
more likely to have above mentioned class II HLA markers, but
no genetic markers have been found for persistent disease. The
objective was to further pinpoint genetic variety of sarcoidosis
prognosis in relation to the HLA markers.
MATERIALS AND METHODS
Study Subjects and Selection Criteria
Study subjects and their characteristics have been previously
described (7). In summary, a total of 188 Finnish patients with
verified pulmonary sarcoidosis had been followed-up for 5–
15 years (Supplementary Table 1). After follow-up the patients
were clinically divided into those with disease resolved within
2 years (n = 90) and to those with persisting activity after 2
years (n= 98). Disease activity was evaluated using the generally
accepted WASOG (World Association of Sarcoidosis and Other
Granulomatous diseases) criteria (10). The clinical examinations
included a chest radiograph, a lung function test (spirometry,
diffusion capacity), electrocardiography (ECG), liver enzymes,
serum calcium, creatinine, serum lysozyme, and serum ACE.
For the WES study, a subset of 72 patients were chosen
(Figure 1). Patients were selected based on disease activity
(resolved disease, n = 36; persistent disease, n = 36). These
subsets were further divided by the HLA markers previously
known to influence disease prognosis in Finnish patients (HLA-
DRB1∗03:01 and HLA-DRB1∗04:01-DPB1∗04:01) yielding in 18
patients with one or both markers (HLA+) and 18 patients with
neither of the markers (HLA–). Same selection was used in both
resolved and persistent patient groups. The Genome Aggregation
Database (gnomAD) (11) was used as control population in the
WES study. GnomAD database consists of exome data from 11
150 Finnish subjects, with no known diseases.
For the replication of the SNPs found in the WES study, the
rest of the original above mentioned 188 Finnish sarcoidosis
patients were genotyped. A control population of 150 healthy
subjects representing the Finnish population (12) was included
for the replication phase.
The study protocol was approved by the Ethics Committee
of the Department of Internal Medicine, Hospital District of
Helsinki and Uusimaa, Helsinki, Finland. All subjects provided
written informed consent for their participation in genetic
association studies.
Whole Exome Sequencing
The DNA extraction have been previously explained (7). The
WES was performed in Institute for Molecular Medicine Finland
(FIMM). 150 ng of gDNA was fragmented with Covaris
E220 evolution instrument (Covaris, Woburn, MA, USA).
Sample libraries and MedExome Enrichment were processed
according to SeqCapEZ HyperCap Workflow User’s Guide
(Roche Nimblegen, Madison, WI, USA). Enrichment was
performed in 4 samples Multiplexed DNA Sample Library Pools
using 1µg of each library. The amplified library was purified with
1.8x Agencourt AMPure XP beads and eluted to 200µl EB-buffer.
Library was quantified for sequencing using 2100 Bioanalyzer
High sensitivity kit. Sequencing was performed with Illumina
HiSeq2500 system in HiSeq High Output mode using v4 kits
(Illumina, San Diego, CA, USA). Read length for the paired-end
run was 2 × 101 bp. 91% of all samples had the target coverage
of 20x.
Variant Calling
Sequencing data were pre-processed using Trimmomatic
(leading:3, trailing:3, sliding window:4:15, illuminaclip:2:30:10,
minlen:36). Paired-end reads passing the filtering were mapped
to the reference genome (GRCh38) using the BWA-MEM
algorithm. Reads were sorted by coordinate and duplicates
were marked with the Picard tools (http://broadinstitute.github.
io/picard/). Base qualities were recalibrated and local indel
realignment performed around indels at the BAM-level using
Genome Analysis Toolkit (GATK) followed by merging of
data by sample and remarking of duplicates with the Picard
tools. Joint genotyping was performed on the whole cohort of
72 samples using GATK HaplotypeCaller and variants were
recalibrated using GATK VariantRecalibrator. GATK tools
were applied as recommended by GATK guidelines and using
GATK resource files that had been converted from GRCh37
to GRCh38 using CrossMap and chain files from EnsEMBL.
Quality control analysis of sequencing data was performed
using the FastQC (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc) with default settings. Additionally, frameshift
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FIGURE 1 | Finnish sarcoidosis patients. Selection criteria based on sarcoidosis prognosis and the presence or absence of the HLA markers (HLA-DRB1*03:01
and/or HLA-DRB1*04:01-DPB1*04:01 haplotype). From each of the HLA positive/negative groups, 18 samples were randomly selected for this study.
indels were excluded due to recognized difficulties calling from
WES data (13).
Annotation and filtering of variants was performed using the
Annovar tool against the RefGene database. Filtering quality
control was as follows: coverage >10, variant quality value >40,
frequency <1%, and assumed to impair protein function. The
mean coverage of exomic regions for each variant was 43X with
individual variant reads varying between 17 and 153X. Reads
were manually checked using Integrative Genomics Viewer
(IGV). Variants with unknown frequency in Finnish population
in the gnomAD database were excluded. Version information
and references of tools used in variant calling are given in
Supplementary Table 2.
Testing for Genetic Association
We analyzed associations for single variants and variant groups
within genes. The associations were evaluated between all the
dichotomous groups (persistent vs. resolved disease, HLA+
persistent vs. resolved disease, and HLA- persistent vs. resolved
disease). For single-variant analysis, the common variants
[minor allele frequency (MAF) > 0.01] were included. The
hypergeometric distribution method in EPACTS software
pipeline (https://genome.sph.umich.edu/wiki/EPACTS) was
used. The gene-based tests were assessed to find whether variants
in each gene are jointly associated with the phenotype. Gene-
based association improves the power to detect rare variants
(MAF < 0.05) in limited sample size. Two methods were used to
test the associations: hypergeometric distribution and SKAT-O
(14) methods implemented in the EPACTS software. SKAT-O
test was used, because it assumes that each variant can have
either positive or negative effect to the phenotype. The p were
corrected for multiple comparisons (number of studied variants)
by using False Discovery Rate (FDR) method and Bonferroni
correction. A value of p < 0.05 was considered statistically
significant. Age, gender, and extrapulmonary manifestations
were used as covariates in all statistical tests. To assess the
functionality of the found variations in protein level, we used Sift
(15) and PolyPhen (16) databases, which both predict possible
impact of an amino acid substitution on the structure and
function of a human protein using straightforward physical
and comparative considerations. To further investigate the
possibly functional effects of the significant SNPs, we used the
Genotype-Tissue Expression (GTEx) Portal (17) to study the
expression quantitative trait loci (eQTL).
For the replication, the SNPs that reached the significant
association level in single-variant and gene-based analysis were
included (Supplementary Table 3). The SNP genotyping was
performed with the Agena Bioscience (Sequenom) MassARRAY
System (Agena Biosciences, SanDiego, California) at the Institute
for Molecular Medicine Finland (FIMM), Helsinki, Finland, with
standard protocols. Genotypes were called using Sequenom’s
MassARRAY Typer software. The allele frequencies between
different groups were compared by a case-control association
analysis (Chi-square χ2 test, PLINK software) (18). We applied
the following quality control filters: minimum call rate per sample
of 90%, SNP minor allele frequency (MAF) > 0.01 and Hardy
Weinberg equilibrium (HWE) > 0.001. Total success rate for
accepted SNP arrays was 95% in the replication samples.
RESULTS
Single-Variant Analysis
Figure 2 shows the Manhattan plot from the single-variant
association tests between resolved and persistent patients
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FIGURE 2 | Manhattan plot from the single-variant association tests between persistent and resolved patients. The X-axis shows chromosome position the Y-axis
shows the negative log of p-values so that higher values represent stronger significance levels. The horizontal red line shows the threshold value for significance.
showing the highest associating peak in the chromosome
19, although not reaching the exome-significance level.
Supplementary Figure 1 shows the quantile-quantile (Q-Q) plot
for the single-variant tests, which demonstrates the similarity
between observed and expected significance values. Table 1
shows the single variants that yielded the strongest associations
in analyses between resolved and persistent, and between HLA+
and HLA– prognosis groups. In analysis between resolved and
persistent patients altogether seven variants associated with the
prognosis. Interestingly, five of these variants were located in
two chromosomal regions: three in chromosome 1 (1p36.21)
and two in chromosome 19 (19q13.42). In HLA+ group, the
associations in these two chromosomal locations remained. In
HLA- patients the chromosomal locations 1p36.21 and 19q13.42
did not associate with the prognosis. None of these associations
remained significant after correcting for multiple testing with
FDR or Bonferroni correction.
Gene-Based Analysis
In gene-based tests, all variants found in the same gene are
grouped to assess the association with the phenotype. Also, in
gene-based analysis the locations 1p36.21 and 19q13.42 showed
associations while not remained significant after correcting with
FDR or Bonferroni correction (Table 2). In location 19q13.42,
variants in gene LAIR1 were also significantly associated
with the prognosis, in addition to previously seen LILRB4
and KIR3DL1/KIRSDS1. Manhattan plot from the gene-based
analysis between HLA+ persistent and resolved patients is
seen in Supplementary Figure 2. No association in locations
1p36.21 and 19q13.42 was seen in HLA- patients. Another
chromosomal location was also seen: in 2p22.3, two genes
were shown to associate with disease prognosis; RASGRP3 with
persistent disease and LTBP1 in resolved disease. However, these
genes did not show significant association in any of the other
subgroup analysis.
Replication Analysis
For the replication analysis, the rest of the Finnish sample set
of 188 samples and 150 Finnish control material were included.
After quality control, total of 150 controls and 181 cases (72
from the WES study and 109 from the replication study) were
included in the analysis. In the replication analysis between
persistent and resolved sarcoidosis patients, the SNPs in the
chromosomal location 1p36.21 were statistically significant as in
the WES study (Table 3). The association in these SNPs was also
found in the analysis between HLA + persistent and resolved
patients, and in contrast to the WES study, these SNPs were
also significantly associated in the HLA-disease subgroup. When
combining the data from the WES and replication studies, the
associations became even stronger in all subgroup analysis. In
chromosomal location 19q13.42, KIR3DL1/KIR3DS1 SNPs did
not replicate and LILRB4 SNPs associated significantly in the
HLA + resolved patients in the combined data set (Table 3).
None of the associations remained statistically significant after
correction with SNP count (data not shown). However, the
MAFs in the control population corresponded to the ones
in the gnomAD Finnish control population except for the
KIR3DL1/KIR3DS1 SNP rs643861, which lacked allele frequency
data in the gnomAD database (Table 3). However, in the NCBI
dbSNP database (https://www.ncbi.nlm.nih.gov/snp/)MAF from
TopMed database is A = 0.185, which resembles MAF found
in our study. TOPMed uses hg38 as a reference genome, in
gnomAD the hg19 is used as a reference genome which might
explain the differences.
The WES study associations were found in single-variation
and gene levels in the chromosomal locations 1p36.21 and
19q13.42. In the replication sample, the associations in the
location 1p36.21 were found only in the SNPs associating
in the single-variation analysis (Supplementary Table 3). In
chromosomal location 19q13.42, none of the other SNPs
in the KIR3DL1/KIR3DS1 associated with the disease (data





































TABLE 1 | Associated variations in single-variant analysis in different Finnish sarcoidosis subgroups based on disease prognosis (persistent, resolved) and HLA markers (HLA+ = HLA–DRB1*03:01 and/or
















1 12719616 1p36.21 0.125 0.375 0.2196 C/T Ser47Pro B/T 0.000915 rs3010877 AADACL3
1 12725527 1p36.21 0.181 0.389 0.3072 T/G Cys125Phe P/T 0.016591 rs7513079 AADACL3
1 12760937 1p36.21 0.139 0.361 0.2346 C/T Phe153Leu B/T 0.00833 rs1132185 C1orf158
1 156267524 1q22 0.000 0.069 0.01 T/C Ile355Val B/T 0.0269443 rs145100575 SMG5
19 54664811 19q13.42 0.208 0.375 0.3021 G/A Asp223Gly B/D 0.01645 rs731170 LILRB4
19 54818581 19q13.42 0.264 0.153 0 G/A Met113Val B/D 0.046766 rs643861 KIR3DL1,
KIR3DS1
20 35434589 20q11.22 0.444 0.347 0.3917 C/A Glu144Ala B/D 0.0397467 rs224331 GDF5
HLA+
1 12719616 1p36.21 0.083 0.361 0.2196 C/T Ser47Pro B/T 0.001023 rs3010877 AADACL3
1 12725527 1p36.21 0.111 0.333 0.3072 T/G Cys125Phe P/T 0.008796 rs7513079 AADACL3
1 12760937 1p36.21 0.111 0.306 0.2346 C/T Phe153Leu B/T 0.020456 rs1132185 C1orf158
1 156267524 1q22 0.000 0.139 0.01 T/C Ile355Val B/T 0.0227273 rs145100575 SMG5
11 5986042 11p15.4 0.083 0.250 0.1899 G/A Trp297Arg B/D 0.0375179 rs4237768 OR52L1
17 37624364 17q12 0.278 0.111 0.2469 C/T Met403Val B/T 0.0429011 rs7216445 DDX52
19 44477666 19q13.31 0.333 0.472 0.4727 G/C Cys272Ser B/T 0.0438416 rs1897820 ZNF180
19 44497294 19q13.31 0.361 0.500 0.4932 A/G Ala41Val B/T 0.0227273 rs2571108 ZNF180
19 54664811 19q13.42 0.139 0.333 0.3021 G/A Met113Val B/D 0.021855 rs731170 LILRB4
19 54818581 19q13.42 0.278 0.111 0 G/A Glu144Ala B/D 0.042901 rs643861 KIR3DL1,
KIR3DS1
HLA–
8 144379425 8q24.3 0.333 0.472 0.4882 C/A Arg17Ser B/T 0.0438416 rs6599528 ADCK5
22 22514169 22q11.22 0.333 0.167 0.2745 T/G Arg488Ser B/D 0.0471713 rs361666 ZNF280A
22 22514173 22q11.22 0.333 0.167 0.2745 C/G Phe486Leu B/T 0.0471713 rs361762 ZNF280A
22 22514885 22q11.22 0.333 0.167 0.2745 G/C Gly249Ala B/T 0.0471713 rs362124 ZNF280A
22 22514894 22q11.22 0.333 0.167 0.2745 C/T Asn246Ser B/T 0.0471713 rs362132 ZNF280A
22 22515221 22q11.22 0.333 0.167 0.275 G/T Tyr137Ser B/T 0.0471713 rs361580 ZNF280A
22 22515224 22q11.22 0.333 0.167 0.2753 C/T Asn136Ser B/T 0.0471713 rs362011 ZNF280A
22 22515418 22q11.22 0.333 0.167 0.2742 A/C Lys71Asn B/T 0.0471713 rs361959 ZNF280A
Bolded are the chromosomal locations were muliple variants were associated.
Resolved patients, n = 36; persitent patients, n = 36; HLA+ resolved, n = 18; HLA+ persistent, n = 18; HLA− resolved, n = 18, HLA− persistent, n = 18.
Predicted function according to PolyPhen and Sift, respectively: B, benign; P, probably damaging; T, tolerated; D, deleterious. MAF, minor allele frequency; gnomAD, The Genome Aggregation Database; AA, amino acid. P values are
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TABLE 2 | Associated genes in gene-based analysis (hypergeometric distribution and SKAT-O methods) in different Finnish sarcoidosis subgroups based on disease







1 109252166–109273493 1p13.3 0.012466754 0.021725009 CELSR2 Persistent
1 12716215–12725527 1p36.21 0.04489705 AADACL3 Resolved
1 12755700–12760937 1p36.21 0.00429823 C1orf158 Resolved
1 156267524–156267524 1q22 0.026944274 0.021343706 SMG5 Resolved
1 23519074–23521037 1p36.12 0.012466754 0.024629574 E2F2 Resolved
2 178532055–178781235 2q31.2 0.028053232 TTN Resolved
2 32947681–33342904 2p22.3 0.02694427 LTBP1 Resolved
2 33524504–33527173 2p22.3 0.02694427 0.03932876 RASGRP3 Persistent
8 144467535–144469561 8q24.3 0.026944274 0.039865155 KIFC2 Resolved
9 128990198–129005527 9q34.11 0.026944274 0.039865155 NUP188 Persistent
11 20160309–20160309 11p15.1 0.040988976 DBX1 Persistent
12 52692557–52692557 12q13.13 0.040988976 KRT77 Persistent
19 17102004–17212090 19p13.11 0.031601364 0.034412198 MYO9B Persistent
19 42079904–42080806 19q13.2 0.026944274 0.039865155 ZNF574 Persistent
19 54361091–54361091 19q13.42 0.04825453 LAIR1 Resolved
19 54664811–54664811 19q13.42 0.01644974 LILRB4 Resolved
19 54818479–54819917 19q13.42 0.04676604 KIR3DL1, KIR3DS1 Persistent
22 27798761–27800302 22q12.1 0.012466754 0.0183 MN1 Persistent
22 32491131–32498513 22q12.3 0.026944274 FBXO7 Persistent
HLA+
1 12716215–12725527 1p36.21 0.01770751 AADACL3 Resolved
1 12755700–12760937 1p36.21 0.00879604 C1orf158 Resolved
1 156267524–156267524 1q22 0.022727273 SMG5 Resolved
3 12004712–12004864 3p25.2 0.04290113 SYN2 Resolved
11 5986042–5986042 11p15.4 0.037517877 OR52L1 Resolved
17 37624364–37628587 17q12 0.04290113 DDX52 Persistent
19 44477645–44497294 19q13.31 0.022727273 ZNF180 Resolved
19 54664811–54664811 19q13.42 0.02185508 LILRB4 Resolved
19 54818479–54819917 19q13.42 0.04290113 KIR3DL1, KIR3DS1 Persistent
HLA–
2 178532055–178781235 2q31.2 0.020455901 TTN Resolved
8 10609233–10623110 8p23.1 0.022727273 0.03576884 RP1L1 Resolved
8 144379425–144392522 8q24.3 0.043841642 ADCK5 Resolved
19 17102004–17212090 19p13.11 0.022727273 0.03576884 MYO9B Persistent
22 22514169–22515418 22q11.22 0.047171298 ZNF280A Persistent
Bolded are the chromosomal locations were multiple genes are associated.
Resolved patients, n = 36; persitent patients, n = 36; HLA+ resolved, n = 18; HLA+ persistent, n = 18; HLA– resolved, n = 18, HLA– persistent, n = 18.
HGD, hypergeometric distribution method.
P values are uncorrected, none of th values remained significant after correcting for multiple tests.
not shown). LAIR1 and KIR3DL3 SNPs did not meet the
Sequenom study design criteria and could not be replicated
(Supplementary Table 3). In chromosomal location 2p22.3, two
genes were shown to associate with the disease prognosis
in the WES study; RASGRP3 with persistent disease and
LTBP1 in resolved disease. In the replication study, only one
SNP in the RASGRP3 and LTBP1 passed the quality control
(Supplementary Table 3) and none of these SNPs associated with
the trait (data not shown).
DISCUSSION
The heterogeneity of sarcoidosis in clinical course and
development of organ involvement suggests that manifestation
of the disease phenotype is a result of multiple genetic variations.
There is a special interest in finding genetic differences between
sarcoidosis patients with different prognosis, because at the
moment prediction of the disease course at the time of diagnosis
is difficult. There are also significant ethnic differences in





































TABLE 3 | Replication of SNPs found in the preliminary Whole-exome sequencing analysis in different Finnish sarcoidosis subgroups based on disease prognosis (persistent, resolved) and HLA markers






























1 12719616 1p36.21 0.125 0.375 0.2196 0.2166 0.1667 0.2885 0.1505 0.3239 C/T 0.000915 0.03142 0.0001009 rs3010877 AADACL3
1 12725527 1p36.21 0.181 0.389 0.3072 0.2866 0.2281 0.375 0.2097 0.3807 T/G 0.0165913 0.01785 0.0003522 rs7513079 AADACL3
1 12760937 1p36.21 0.139 0.361 0.2346 0.2261 0.1667 0.3173 0.1559 0.3352 C/T 0.0083299 0.009143 7.031E-05 rs1132185 C1orf158
19 54664811 19q13.42 0.208 0.375 0.3021 0.2834 0.3421 0.3558 0.2903 0.3636 G/A 0.0164497 0.8325 0.1369 rs731170 LILRB4
19 54818581 19q13.42 0.264 0.153 0 0.2677 0.2544 0.2692 0.2796 0.233 G/A 0.046766 0.8033 0.3103 rs643861 KIR3DL1,
KIR3DS1
HLA+
1 12719616 1p36.21 0.083 0.361 0.2196 0.2166 0.1071 0.22 0.09375 0.314 C/T 0.0010228 0.2128 5.27E-06 rs3010877 AADACL3
1 12725527 1p36.21 0.111 0.333 0.3072 0.2866 0.1071 0.32 0.1094 0.3721 T/G 0.008796 0.03565 2.88E-07 rs7513079 AADACL3
1 12760937 1p36.21 0.111 0.306 0.2346 0.2261 0.07143 0.26 0.09375 0.3256 C/T 0.0204559 0.04265 2.10E-06 rs1132185 C1orf158
19 54664811 19q13.42 0.139 0.333 0.3021 0.2834 0.3929 0.42 0.25 0.407 G/A 0.0218551 0.8152 0.004529 rs731170 LILRB4
19 54818581 19q13.42 0.278 0.111 0 0.2677 0.25 0.3 0.2812 0.2674 G/A 0.0429011 0.6378 0.8511 rs643861 KIR3DL1,
KIR3DS1
HLA–
1 12719616 1p36.21 0.1667 0.3056 0.2196 0.2166 0.186 0.3519 0.1803 0.3333 C/T 0.1653 0.02743 0.01049 rs3010877 AADACL3
1 12725527 1p36.21 0.25 0.3333 0.3072 0.2866 0.2674 0.4259 0.2623 0.3889 T/G 0.4367 0.05197 0.05005 rs7513079 AADACL3
1 12760937 1p36.21 0.1667 0.3056 0.2346 0.2261 0.1977 0.3704 0.1885 0.3444 C/T 0.1653 0.02409 0.01001 rs1132185 C1orf158
*Resolved patients, n = 36; persistent patients, n = 36; HLA+ resolved, n = 18; HLA+ persistent, n = 18; HLA– resolved, n = 18, HLA– persistent, n = 18.
**Resolved patients, n = 52; persistent patients, n = 57; HLA+ resolved, n = 25; HLA+ persistent, n = 14; HLA– resolved, n = 27, HLA– persistent, n = 43.
***Resolved patients, n = 88; persistent patients, n = 93; HLA+ resolved, n = 43; HLA+ persistent, n = 32; HLA– resolved, n = 45, HLA– persistent, n = 61.
Predicted function according to PolyPhen and Sift, respectively: B, benign; P, probably damaging; T, tolerated; D, deleterious.
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disease development and prognosis in different populations
(19). These differences represent a compelling need for
ethnic-selective biomarkers to assess disease progression in
diverse populations.
Here we present results from WES study in Finnish
sarcoidosis patients. The strategy was to sequence groups
of sarcoidosis patients with known differences in prognosis
to identify variants that could alter functional properties of
proteins. In Finnish sarcoidosis patients, certain HLA markers
(HLA-DRB1∗03:01, HLA-DRB1∗04:01-DQB1∗04:01) have been
shown to be more common in patients with sarcoidosis disease
resolving within 2 years, i.e., good prognosis disease. The
aim of this study was to further pinpoint genetic variety
in different sarcoidosis prognosis groups in relation to these
HLA markers.
The most strongly associated and replicated chromosomal
location was found in 1p36.21, containing two genes (AADACL3
and C1orf158). This region has also been found to associate with
familial sarcoidosis in a recent WES study in German patients
(20). However, in French WES study of familial sarcoidosis,
no association with this region was found (21). In our study,
variations in these genes were associated with disease resolution
independent of the HLA markers DRB1∗03:01 and DRB1∗04:01.
The found variations in AADACL3 are predicted to be benign,
but the variation in C1orf158 is thought to alter the function
of the protein. However, the functionality of these variants
in sarcoidosis predisposition is unclear at the moment. The
variants rs3010877 in AADACL3 and rs1132185 in C1orf158
are known to act as eQTLs in not sun exposed skin, but
no clear in sarcoidosis pathogenesis is evident. Due to LD,
it is also possible that association derives from elsewhere in
the chromosome. However, no functionally plausible genes
reside in near proximity of these genes, while the further
region in 1p36 has been associated with resolution of chest
findings in sarcoidosis patients (22). Therefore, further studies
are needed to evaluate the possible causality of these genes and
sarcoidosis susceptibility.
In the WES study, another interesting chromosomal region
was seen in 19q13.42 (LILRB4, KIR3DL1/KIR3DS1, and LAIR1).
In the replication part of the study, only association with LILRB4
remained statistically significant when WES and replication data
were combined, the other associations were weakened or could
not been replicated. It should be noted, that the size of the
replication material is still relatively small, and possible true
causality cannot be ruled out.
The 19q13.42 region, called the Leukocyte Receptor Complex
(LRC), comprises a large set of genes encoding immunoglobulin
superfamily receptors (23). The leukocyte immunoglobulin-
like receptors (LILR) can interact with the HLA class I (24)
and are expressed by a range of immunologically active cells,
including natural killer (NK) and antigen-presenting cells (APCs)
(25). LILRs have both activating and inhibitory effects (26).
Previously no associations have been found between LILRB4
and sarcoidosis, but variations in this gene have shown to
increase risk of another immune-mediated disease, systemic
lupus erythematosus (SLE) (27). In our study, variations in this
gene associated with good prognosis patients having the good
prognosis HLA Class II markers. LILRB4 belongs to inhibitory
receptors expressed on dendritic cells and has been shown to
interact with the HLA-G. (28). LILRB4-HLA-G interaction has
been demonstrated to limit the activation of dendritic cells
(29), which are important APCs in sarcoidosis inflammation.
In sarcoidosis, the association with HLA-II is thought to be
more important, but it should be noted that limited information
exists in relation to HLA-G in sarcoidosis. In one study, the
HLA-G variation was seen in sarcoidosis patients (30). Also,
there is a strong LD in the MHC region, and it is possible
that patients with the HLA class II markers have haplotypes
containing the HLA class I as well. The combination of
these MHC variations, with the variants in the LILRB4, could
alter the immune reaction in sarcoidosis and lead to self-
resolving disease.
In addition to LILRB4, in the WES study, association
was found with variants in LAIR1 and KIR3DL1/KIR3DS1.
Leukocyte-associated immunoglobulin-like receptor-1 (LAIR1)
has been shown to inhibit T and NK cell activation (31), but
there are no known HLA ligands for this receptor. In our
study, association with variants in the LAIR1 was seen when
persistent and resolved patients were compared. No association
was evident with the HLA markers, which is in concordance
with the notion that there are no known HLA ligands for this
protein. No association have been found between this gene
and sarcoidosis, but also this immune-modulator gene has been
shown to have effect in SLE (32). However, this association was
seen only in gene-based analysis and with single method. Due
to technical issues, the variation could not be replicated, so the
effect should be considered cautiously. The other association
seen only in the WES study encode KIRs, receptors expressed
mainly on the surface of natural killer (NK) cells. Most diverse
of the KIR genes is locus KIR3DL1/KIR3DS1 which associated
with persistent sarcoidosis in our study. The gene encodes both
inhibitory (3DL1) and activating (3DS1) receptors (33), so either
or both of these functions could be affected, shifting the course
of the disease toward chronic. In a recent WES study of three
families sharing pediatric sarcoidosis, the KIR3DL1/KIR3DS1 in
gene level was found to be shared in these families (34). To our
knowledge, no case-control study has found association in KIR
genes and sarcoidosis.
There are some limitations in this study. Sarcoidosis being
a relatively rare disease, the collection of large data sets is
demanding in a small country as Finland. Therefore, due
to relatively small sample size, the power might have not
been sufficient to detect all associations, however, the gene-
based analysis in the WES study and the replication sample
increases the power. Because of the patient selection based
on the HLA markers, the analysis between all persistent and
resolved patients has some statistical limitations. However, in
the replication study, the whole Finnish sarcoidosis sample
is involved. The other confounding factors: gender, age
and extrapulmonary manifestations, were conditioned in
all analyses.
In summary, we used WES to further characterize genetic
differences between persistent and resolved sarcoidosis patients
and to test the hypothesis whether different variations
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are associated in relation to the class II markers (HLA-
DRB1∗03:01/HLA-DRB1∗04:01-DPB1∗04:01). An association
with resolved disease raised in the chromosomal region 1p36.21,
a region which has recently been associated with sarcoidosis in
another WES study. Another interesting chromosomal region
peaked, 19q13.42, but in the replication study the association
weakened. However, due to relatively small sample size, the true
causality of these variants should be evaluated in a larger data set.
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